Best et al. (2015) evidenced mRNA profiles of tumor-educated blood platelets (TEPs) were different between KRAS mutant pancreatic cancer and KARS wild-type. TEPs RSL24D1 mRNA was negatively related to early pancreatic cancer compared to healthy controls (Xue et al., 2018). Moreover, the platelet proteome of patients with head of pancreas cancer (stage I-II) is significantly different from that of healthy individuals of equivalent sex and age (Sabrkhany et al., 2017, 2018). Here, KRAS is linked to pancreatic neoplasm.